CM
RCUS icon

Capula Management’s Arcus Biosciences RCUS Stock Holding History

Capula Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,053
Closed -$228K – 818
2025
Q1 		$228K Buy
+29,053
New +$337K ﹤0.01% 492
2024
Q3 		– Sell
-55,709
Closed -$848K – 615
2024
Q2 		$848K Buy
+55,709
New +$899K 0.01% 181

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Capula Management's RCUS Position: Q2 2025 in Review

Capula Management sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 29,053 shares — an estimated $228K sold.

Capula Management first reported a position in RCUS in Q2 2024 and held it in 2 quarters. The position peaked at $848K in Q2 2024. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Capula Management reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Capula Management sold 29,053 Arcus Biosciences shares in Q2 2025, an estimated $228K.
  • Capula Management first reported a position in Arcus Biosciences in Q2 2024 and held it in 2 quarters.
  • Capula Management's Arcus Biosciences position peaked at $848K in Q2 2024.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.